Skip to search formSkip to main contentSkip to account menu

NVP ABE171

Known as: 4-(8-benzo(1,2,5)oxadiazol-5-yl-(1,7)naphthyridin-6-yl)benzoic acid, NVP-ABE171, NVPABE171 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

NaphthyridinesOxadiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
2012
2012
Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils.
Many techniques are being used to examine the status of circulating human basophils including the enhanced expression of a… 
2012
2012
Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
The family of fibroblast growth factors (FGFs) and FGF receptors (FGFRs) plays a critical role in cell proliferation and survival… 
2008
2008
Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine.
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against the human immunodeficiency virus type 1 (HIV-1… 
Highly Cited
2004
Highly Cited
2004
Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
Expression of the epidermal growth factor (EGF) and activation of its receptor (EGFR), a tyrosine kinase, are associated with… 
2004
2004
K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
Highly Cited
2002
Highly Cited
2002
1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. We report the… 
Highly Cited
2002
Highly Cited
2002
Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity.
This study was performed to determine the effects of a high-fat diet on glucose metabolism after an oral glucose challenge in… 
2002
2002
Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti…
We investigated the pharmacology of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, by… 
1998
1998
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
Objective:To investigate the pharmacokinetics of nelfinavir (NFV) administered alone and in combination with nevirapine (NVP) to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)